Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Immutep (DE:YP1A)
FRANKFURT:YP1A
Immutep (YP1A) Stock Price & Analysis
0 Followers
YP1A Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€1.35 - €2.90
Previous Close€2.08
Volume0.00
Average Volume (3M)727.00
Market Cap
€258.42M
Enterprise Value€184.53M
Total Cash (Recent Filing)AU$123.42M
Total Debt (Recent Filing)AU$1.23M
Price to Earnings (P/E)-8.7
Beta1.11
Next Earnings
Aug 28, 2024EPS Estimate
-€0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.24
Shares Outstanding1,187,306,209
10 Day Avg. Volume0
30 Day Avg. Volume727
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)21.60
Price to Sales (P/S)778.96
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€6.59Price Target Upside216.99% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Immutep News
PremiumCompany Announcements
Immutep’s Efti Shows Promise in Cancer Trial
PremiumCompany Announcements
Immutep Advances Novel Autoimmune Therapy with Phase I Trial
Options Prices
Currently, No data available
---
Ownership Overview
0.00%
Insiders
0.05% Mutual Funds
1.53% Other Institutional Investors
98.42% Public Companies and
Individual Investors
YP1A FAQ
What was Immutep’s price range in the past 12 months?
Immutep lowest stock price was €1.35 and its highest was €2.90 in the past 12 months.
What is Immutep’s market cap?
Currently, no data Available
When is Immutep’s upcoming earnings report date?
Immutep’s upcoming earnings report date is Aug 28, 2024 which is in 121 days.
How were Immutep’s earnings last quarter?
Immutep released its earnings results on Feb 27, 2024. The company reported -€0.17 earnings per share for the quarter, missing the consensus estimate of -€0.126 by -€0.043.
Is Immutep overvalued?
According to Wall Street analysts Immutep’s price is currently Undervalued.
Does Immutep pay dividends?
Immutep does not currently pay dividends.
What is Immutep’s EPS estimate?
Immutep’s EPS estimate is -€0.12.
How many shares outstanding does Immutep have?
Immutep has 118,883,450 shares outstanding.
What happened to Immutep’s price movement after its last earnings report?
Immutep reported an EPS of -€0.17 in its last earnings report, missing expectations of -€0.126. Following the earnings report the stock price went up 0.98%.
Which hedge fund is a major shareholder of Immutep?
Among the largest hedge funds holding Immutep’s share is Oracle Investment Management Inc. It holds Immutep’s shares valued at 1M.
---
Immutep Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€6.59 (216.99% Upside)
€6.59 (216.99% Upside)
Blogger Sentiment
Bullish
DE:YP1A Sentiment 100%
Sector Average 70%
Sector Average 70%
Technicals
SMA
Positive
20 days / 200 days
Momentum
42.13%
12-Months-Change
Fundamentals
Return on Equity
-41.05%
Trailing 12-Months
Asset Growth
44.82%
Trailing 12-Months
Company Description
Immutep
Immutep Ltd. is a biotechnology company, which engages in the research and development of immunotherapeutic treatments for cancer and autoimmune diseases. Its product is IMP321, which involves in clinical development for the treatment of breast cancer and melanoma. The company was founded on May 21, 1987 and is headquartered in Sydney, Australia.
---
YP1A Stock 12 Months Forecast
Average Price Target
€6.59
▲(216.99% Upside)
Technical Analysis
Immutep
―
Gritstone Oncology
―
Immuron
―
ImmunoCellular Therapeutics
―
Arrowhead Pharmaceuticals
―
Best Analysts Covering YP1A
1 Year
1 Year Success Rate
5/9 ratings generated profit
1 Year Average Return
+6.31%
reiterated a buy rating 6 months ago
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 55.56% of your transactions generating a profit, with an average return of +6.31% per trade.
---